CSRxP STATEMENT ON PCMA LAWSUIT CHALLENGING TRUMP ADMINISTRATION’S REBATE RULE

Misguided Policy Published in Violation of Legally Required Process for Public Input, Will Increase Premiums for Seniors, Do Nothing to Lower Drug Prices and Pad Big Pharma’s Bottom Line

For Immediate Release
Contact: Jon Conradi
860-235-3884
[email protected]

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Tuesday after the Pharmaceutical Care Management Association’s (PCMA) announced a lawsuit against the Trump administration’s final rule aimed at eliminating prescription drug rebates in Medicare Part D.

“The Big Pharma-backed Rebate Rule was not only issued in violation of a legally required process for public input, but the administration’s own actuaries found it would do nothing to lower drug prices while increasing premiums on Medicare Part D beneficiaries, costing taxpayers more than $200 billion and handing drug companies a more than $100 billion bailout,” said CSRxP executive director Lauren Aronson. “CSRxP supports PCMA’s lawsuit challenging this misguided proposal and looks forward to working with the next administration and lawmakers to focus drug pricing efforts on market-based solutions to increase transparency, boost competition and hold Big Pharma accountable.”

Get The Facts on the Rebate Rule

Learn more about the misguided Rebate Rule HERE.

Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.